Astria Therapeutics Inc. (ATXS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Cantor Global Healthcare Conference 2025 September 4, 2025 3:20 PM EDT Company Participants Jill Milne - Co-Founder, CEO, President & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay. Great. Good afternoon, everyone, and welcome to the next session at the Cantor Global Healthcare Conference.
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.
